At Rigel Pharmaceuticals, our purpose is to discover, develop and provide novel therapies.
In particular, we are focused on hematologic disorders and cancer. We see great opportunity to help patients who have diseases where few or no approved treatment options exist.
Rigel’s FDA approved products:
Rigel works with partners to bring our products to markets outside of the U.S. We also explore new opportunities to expand our product and development pipeline through strategic collaborations that align with our commitment to bring new therapies to patients with unmet medical needs.
Our clinical programs include an interleukin receptor-associated kinase 1 and 4 (IRAK1/4) inhibitor program that is currently being evaluated in a Phase 1b study in patients with lower-risk myelodysplastic syndrome. In addition, Rigel is collaborating with Eli Lilly to develop Rigel’s receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors in immunological and neurodegenerative diseases.
TAVALISSE Full Prescribing InformationREZLIDHIA Full Prescribing Information, including Boxed WARNING
GAVRETO Full Prescribing Information